A Phase III Randomized Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy.

Trial Profile

A Phase III Randomized Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Oct 2015

At a glance

  • Drugs Carboplatin; Doxorubicin liposomal
  • Indications Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jun 2012 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
    • 12 Jun 2012 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 29 Dec 2009 Final survival results published in Gynecologic Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top